Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, focuses on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs).

The company has shown impressive YoY revenue growth driven by a robust non-GPL business expansion of 39.7%, highlighting strategic new product launches.

Alivus is heavily invested in capacity expansion across multiple sites, strengthening its production capabilities and future market presence.

Management remains confident about sustaining margins despite the absence of PLI benefits, supported by a strong pipeline and operational efficiencies.